Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund lowered its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 70.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 228,625 shares of the company's stock after selling 551,375 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned approximately 0.27% of Syndax Pharmaceuticals worth $4,694,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of SNDX. BVF Inc. IL purchased a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth $40,519,000. Avoro Capital Advisors LLC lifted its stake in Syndax Pharmaceuticals by 65.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,222,222 shares of the company's stock worth $91,242,000 after acquiring an additional 1,666,667 shares during the period. Kynam Capital Management LP grew its holdings in Syndax Pharmaceuticals by 41.5% during the 4th quarter. Kynam Capital Management LP now owns 5,660,000 shares of the company's stock worth $122,313,000 after acquiring an additional 1,660,000 shares in the last quarter. Avidity Partners Management LP increased its position in Syndax Pharmaceuticals by 40.0% during the 4th quarter. Avidity Partners Management LP now owns 3,950,000 shares of the company's stock valued at $85,360,000 after purchasing an additional 1,129,000 shares during the period. Finally, Iron Triangle Partners LP bought a new stake in shares of Syndax Pharmaceuticals in the 1st quarter valued at about $23,159,000.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX traded up $0.13 during trading on Friday, hitting $18.82. The company's stock had a trading volume of 559,815 shares, compared to its average volume of 1,272,483. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $11.22 and a fifty-two week high of $25.34. The company has a market cap of $1.60 billion, a PE ratio of -5.84 and a beta of 0.91. The business's 50 day simple moving average is $19.69 and its 200-day simple moving average is $20.83.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.11. The company had revenue of $3.50 million during the quarter. The firm's revenue was up 3499999990.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.64) earnings per share. Analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNDX has been the topic of a number of recent research reports. HC Wainwright increased their price objective on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. Stifel Nicolaus increased their target price on Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Wednesday, June 26th. JPMorgan Chase & Co. reduced their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. Citigroup upped their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a "buy" rating in a research note on Friday, August 16th. Finally, Bank of America lifted their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.30.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).